CClinicalTrials.gg
Active, not recruitingNCT06773910TIGOS-LSUpdated Sep 21, 2026

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

A Phase 2 interventional study of BMS-986489 and Durvalumab in Limited Stage Small Cell Lung Cancer, sponsored by SCRI Development Innovations, LLC. Active, not recruiting at 34 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by SCRI Development Innovations, LLC · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.

The main goals of this study are to:

  • Evaluate the efficacy of BMS-986489 vs durvalumab
  • Evaluate the safety profile of BMS-986489
Read the detailed description

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in participants with limited-stage (LS)-small-cell lung cancer (SCLC). Participants will receive concurrent chemotherapy and radiotherapy according to standard guidelines for treatment of LS-SCLC without progressive disease prior to randomization. Eligible participants will be randomly assigned to receive either BMS-986489 (atigotatug + nivolumab as a fixed-dose combination; Arm A) or durvalumab (Arm B) as consolidation therapy. Atigotatug is a first-in-class, fully human IgG1 antibody being developed for the treatment of SCLC. Atigotatug specifically binds to fuc-GM1 on the tumor cell. Nivolumab is a monoclonal anti-PD-1 antibody. Combining atigotatug with another immunotherapy may provide enhanced antitumor effects.

02

Conditions studied

  • Limited Stage Small Cell Lung Cancer

Keywords

  • limited stage small cell lung cancer
  • limited stage small cell lung carcinoma
  • LS-SCLC
  • Limited-stage SCLC
  • Nivolumab
  • Opdivo
  • fucosyl-monosialoganglioside-1
  • fuc-GM1
  • programmed cell death protein 1
  • PD-1 inhibitor
  • anti-PD-1 antibody
  • Durvalumab
  • Imfinzi
  • PD-L1 inhibitor
  • Anti-PD-L1 antibody
  • Limited-stage (LS)-small-cell lung cancer (SCLC)
  • BMS-986489
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • At least 18 years-of-age at the time of signature of the Informed Consent Form (ICF)
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (Appendix A)
  • Histologically or cytologically confirmed pulmonary SCLC, evaluable by RECIST v1.1
  • Limited-stage (LS) disease as determined by positron emission tomography (PET) scan prior to initiation of chemotherapy and radiation therapy
  • Completed concurrent chemotherapy and radiotherapy for LS-SCLC without progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (computed tomography [CT] scan chest/abdomen/pelvis; Appendix B) within 42 days before date of randomization and first dose of study treatment

    • Chemotherapy should consist of a platinum and IV etoposide. Participants who received at least 3 cycles of chemotherapy will be eligible to participate.
    • Radiotherapy should be administered per institutional guidelines
  • Prophylactic cranial irradiation (PCI) may be delivered at the discretion of the Investigator and institutional guidelines. PCI, if applicable, must be conducted after the end of chemoradiotherapy and completed between 14 and 42 days before date of randomization and first dose of study treatment.
  • Adequate hematologic and organ function
  • Willingness to abide by protocol defined contraceptive requirements for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Small-cell cancer not pulmonary in origin
  • Large cell neuroendocrine carcinoma
  • ES-SCLC
  • Mixed SCLC and NSCLC histologic features; diagnosis of NSCLC; or EGFR-activating, mutation-positive NSCLC that has transformed to SCLC
  • History of severe hypersensitivity reaction to monoclonal antibodies
  • Known hypersensitivity to any excipients of atigotatug, nivolumab, or durvalumab
  • Grade ≥2 peripheral neuropathy by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
  • Active, prior, or suspected autoimmune disease, including autoimmune neurologic disorders such as paraneoplastic syndrome involving the CNS, peripheral sensory/motor nerves, or neuromuscular junction. Exceptions to this criterion include:

    • Type 1 diabetes mellitus
    • Hypothyroidism requiring only hormone replacement
    • Skin disorders not requiring systemic treatment
    • Autoimmune conditions not expected to recur during the study
  • Diseases or conditions requiring chronic systemic corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive therapy within 14 days of starting study treatment. Limited-course (\<2 weeks' duration) oral steroids (10 mg prednisone or equivalent) are permitted. Bronchodilators, inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
  • History of solid organ or bone marrow transplantation
  • History of Grade ≥2 pneumonitis (excepting resolved infective pneumonitis)
  • Any of the following cardiac criteria, currently or within the last 3 months:

    • Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting electrocardiograms (ECGs), e.g., complete left bundle branch block, third-degree heart block, atrial fibrillation not rate controlled. Certain conditions may be considered through discussion with the Medical Monitor.
    • Congestive heart failure (New York Heart Association [NYHA] > Grade 2) or classified as Class 3 or 4 by the NYHA Functional Classification (Appendix D)
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncontrolled hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval (Appendix E). Certain conditions may be considered through discussion with the Medical Monitor.
    • Participants with a left ventricular ejection fraction \<55% or the lower limit of normal of the institutional standard
    • Uncontrolled hypertension, defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management
    • Active coronary artery disease, including unstable or newly diagnosed angina
    • Myocardial infarction
    • History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes)
    • History or current diagnosis of myocarditis
  • As judged by the Investigator, participants with serious or uncontrolled medical disorders
  • Presence of other active invasive cancers. Participants with a previously treated malignancy will be eligible to participate if treatment of that malignancy was completed at least 2 years before date of screening and the participants has no evidence of disease. Exceptions to this criterion include appropriately treated basal cell carcinoma of the skin; in situ carcinoma of uterine cervix; localized prostate cancer that has been definitively treated; or other local tumors considered cured by local treatment.
  • Received sequential chemotherapy and radiotherapy as a definitive treatment for LS-SCLC
  • Treatment with any of the following:

    • Any systemic anticancer chemotherapy, small molecule, biologic, or hormonal agent from a previous treatment regimen or clinical study within 21 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment
    • Wide-field radiotherapy (including therapeutic radioisotopes such as strontium-89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study treatment or has not recovered from side effects of such therapy
    • Prior systemic treatment for LS-SCLC, with the exception of chemoradiotherapy and PCI
    • Prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed cell death ligand 2 (anti-PD-L2), anti-CD137, anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
    • Prior treatment with fuc-GM-1 vaccine or targeted agent or similar vaccine targeting ganglioside antigens
    • Current treatment with immunosuppressive medications
    • Live attenuated vaccine within 100 days before first dose of study treatment
  • Major surgery (excluding placement of vascular access) within 4 weeks of date of screening
  • With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment. Note: Participants with chronic Grade 2 toxicities who are asymptomatic or adequately managed with stable medication may be eligible with approval by the Medical Monitor or Principal Investigator.
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    BMS-986489 (atigotatug + nivolumab)

    Participants will receive a fixed dose of BMS-986489 (atigotatug + nivolumab) intravenously each cycle. Cycles will be 28 days. Up to 125 participants will be enrolled into this arm.

    Drug: BMS-986489

  • Active comparator
    Durvalumab

    Participants will receive standard of care Durvalumab intravenously each cycle. Cycles will be 28 days. Up to 125 participants will be enrolled into this arm.

    Drug: Durvalumab

Interventions

  • DrugBMS-986489

    BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.

  • DrugDurvalumab

    Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.

05

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of BMS-986489 vs durvalumab by Overall Survival (OS).

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause.

    Time frame: From date of randomization up to 5 years. Every 8 weeks for participants who stopped treatment before disease progression and before completing 6 months of treatment and every 12 weeks for participants who stopped treatment before disease progression and

Secondary outcomes

  1. Evaluate the efficacy of BMS-986489 vs durvalumab by Progression Free Survival (PFS).

    Progression Free Survival (PFS) is defined as the time from start of study treatment to the date of an event, defined as the first documented radiological progression or death due to any cause.

    Time frame: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

  2. Evaluate the efficacy of BMS-986489 vs durvalumab Objective Response Rate (ORR).

    Objective Response Rate (ORR) is defined as the proportion of participants with BOR of CR or PR according to RECIST v1.1.

    Time frame: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

  3. Evaluate the efficacy of BMS-986489 vs durvalumab by Clinical Benefit Rate (CBR).

    Clinical Benefit Rate (CBR) is defined as the proportion of participants with BOR of CR or PR, or participants with SD lasting at least 180 days (i.e., ≥6 months) according to RECIST v1.1.

    Time frame: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

  4. Evaluate the efficacy of BMS-986489 vs durvalumab by Disease Control Rate (DCR).

    Disease Control Rate (DCR) is defined as the proportion of participants with BOR of CR, PR, or SD according to RECIST v1.1

    Time frame: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

  5. Evaluate the efficacy of BMS-986489 vs durvalumab by Duration of Response (DoR).

    Duration of Response (DoR) is defined as the duration from the first documented response (Complete Response (CR), Partial Response (PR), or Stable Disease (SD), according to RECIST v1.1) to the date of first documented disease progression or death.

    Time frame: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

  6. Evaluate the efficacy of BMS-986489 vs durvalumab by Time to Progression (TtP).

    Time to Progression (TtP) is defined as the time from the date of randomization to the date of first documented disease progression, according to RECIST v1.1.

    Time frame: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

  7. Evaluate the efficacy of BMS-986489 vs durvalumab by time to development of central nervous system (CNS) metastasis.

    Time to development of central nervous system (CNS) metastasis is defined as the time from the date of randomization to the date of first documented CNS metastasis.

    Time frame: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

  8. Evaluate the number of participants with adverse events following administration of BMS-986489.

    Adverse Events to be evaluated per CTCAE v5.0 criteria from first dose of BMS-986489 to 100 days after the last dose of BMS-986489.

    Time frame: From Cycle 1 Day 1 to 100 days after the last dose of BMS-986489. Each cycle is 28 days.

06

Study locations

34 sites
  • Southern Cancer Center
    Daphne, Alabama 36526, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • Florida Cancer Specialists - South
    Fort Myers, Florida 33901, United States
  • University of Miami - Sylvester Cancer Center
    Miami, Florida 33136, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Florida Cancer Specialists - North
    Orange City, Florida 32763, United States
  • Cancer Care Centers of Brevard
    Palm Bay, Florida 32901, United States
  • Florida Cancer Specialists - East
    West Palm Beach, Florida 33401, United States
  • Piedmont Healthcare - Atlanta
    Atlanta, Georgia 30309, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Baptist Health - Corbin
    Corbin, Kentucky 40701, United States
  • Baptist Health - Lexington
    Lexington, Kentucky 40503, United States
  • Baptist Health - Louisville
    Louisville, Kentucky 40207, United States
  • Minnesota Oncology Hematology
    Maple Grove, Minnesota 55369, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • White Plains Hospital Physician Associates
    White Plains, New York 10601, United States
  • Carolina Cancer Research Center
    Wilson, North Carolina 27896, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • The Ohio State University - Arthur James Cancer Hospital & Solove Research Institute
    Columbus, Ohio 43210, United States
  • Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center
    Columbus, Ohio 43219, United States
  • Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center)
    Eugene, Oregon 97401, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee 37909, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Texas Oncology - West Texas
    Amarillo, Texas 79124, United States
  • Texas Oncology- Austin
    Austin, Texas 78705, United States
  • Texas Oncology - Gulf Coast
    Beaumont, Texas 77702, United States
  • Texas Oncology - DFW
    Dallas, Texas 75246, United States
  • Texas Oncology - Northeast Texas
    Denison, Texas 75020, United States
  • Texas Oncology - San Antonio
    San Antonio, Texas 78240, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA)
    Salem, Virginia 24153, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06773910
Lead sponsor
SCRI Development Innovations, LLC
Collaborators
Bristol-Myers Squibb
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Mar 11, 2025
Primary completion
May 2032 (estimated)
Completion
Sep 2032 (estimated)
Last update
Sep 21, 2026

Study contacts

Melissa Johnson, MD
study chair · SCRI Development Innovations, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion